Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinical stage immuno-oncology company Imugene (IMU) granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer
  • The patent entitled “A Vaccine Composition and Uses Thereof” protects the method of composition and use of HER-Vaxx in Europe until 2036
  • HER-Vaxx is designed to treat tumours that over express the HER-2 receptor, a cause of gastric, breast, ovarian, lung and pancreatic cancers
  • The company says pre-clinical trials show HER-Vaxx stimulates a potent antibody response to the HER-2 receptor
  • Shares were trading at 28 cents at close of market January 27

Clinical stage immuno-oncology company Imugene (IMU) has been granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer.

The patent entitled “A Vaccine Composition and Uses Thereof” protects the method of composition and use of HER-Vaxx in Europe until 2036.

HER-Vaxx is designed to treat tumours that over express the HER-2 receptor, a cause of gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2.

The company said pre-clinical trials show HER-Vaxx stimulates a potent antibody response to the HER-2 receptor.

MD and CEO Leslie Chong said attaining the European patent is an important milestone.

“Attaining the key European patent is an important milestone and is another major pharmaceutical market to grant patent protection for HER-Vaxx until 2036,” she said.

The company said its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours.

Shares were trading at 28 cents at close of market January 27.

IMU by the numbers
More From The Market Herald

" Woodside Petroleum (ASX:WPL) makes official name change

Woodside Petroleum (ASX:WPL) has changed its name to Woodside Energy Group, effective from Wednesday, May 25.

" Johns Lyng Group (ASX:JLG) CEO and COO sell shares worth $12.5m

Johns Lyng Group (ASX:JLG) has advised Managing Director and CEO Scott Didier, along with Executive Director and…
IGO (ASX:IGO) - CEO & Managing DIrector, Peter Bradford

" IGO (ASX:IGO) produces first battery-grade lithium hydroxide from Kwinana refinery

IGO (ASX:IGO) has produced the first battery-grade lithium hydroxide from the Kwinana Lithium Hydroxide Refinery in…

" Seafarms (ASX:SFG) appoints Rod Dyer as CEO among executive changes

Seafarms (ASX:SFG) has appointed Rod Dyer as CEO, effectively immediately.